There is an urgent need for accurate, fast point-of-care tests that simultaneously provide diagnostic and prognostic information about a patient entering the hospital with symptoms of acute heart failure.
Heart failure is characterized by a large variation in the severity and prognosis of the disease. It ranges from mild disease that is in general relatively easily managed with classical therapy to advanced illness requiring intensive therapy with mechanical support or heart transplantation.
The clinical effectiveness of the current generation of heart failure biomarkers is limited by the need to repeatedly measure multiple individual markers. Such approach is required to generate a full risk profile of a patient suspected of heart failure. In general, each biomarker carries information that is predominantly diagnostic or prognostic and only reflects one single part of the complex disease mechanisms underlying heart failure. A full risk profile of a patient entering the hospital with symptoms of acute heart failure is required to optimally assess the clinical condition. Most clinicians would therefore like to combine different types of biomarkers in a multi-marker panel.
The goal of Mirnext is to develop a multi-marker heart failure test that can favorably compete with the established heart failure markers in terms of diagnostic and prognostic accuracy. The patient will benefit from a single test that quickly probes many different disease mechanisms and provides an extensive cardiac risk profile that will help the clinician to initiate targeted treatments